Reduced Chrna7 expression in C3H mice is associated with increases in hippocampal parvalbumin and glutamate decarboxylase-67 (GAD67) as well as altered levels of GABAA receptor subunits

Neuroscience

Volumn 273, Issue , 2014, Pages 52-64

  Bates, R C ^a,b,c   Stith, B J ^c   Stevens, K E ^a,b   Adams, C E ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^c Department of Integrative Biology University of Colorado Denver Downtown Denver Campus ^*  (United States)

Author keywords

Chrna7; Glutamate decarboxylase 67 (GAD67); Parvalbumin; Schizophrenia; aminobutyric acid (GABA)

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; 4 AMINOBUTYRIC ACID A RECEPTOR ALPHA3; 4 AMINOBUTYRIC ACID A RECEPTOR ALPHA4; 4 AMINOBUTYRIC ACID A RECEPTOR DELTA; 4 AMINOBUTYRIC ACID A RECEPTOR GAMMA2; BUNGAROTOXIN RECEPTOR; GLUTAMATE DECARBOXYLASE 67; PARVALBUMIN; UNCLASSIFIED DRUG; CHRNA7 PROTEIN, MOUSE; GABRA3 PROTEIN, MOUSE; GABRD PROTEIN, MOUSE; GABRG2 PROTEIN, MOUSE; GLUTAMATE DECARBOXYLASE; GLUTAMATE DECARBOXYLASE 1;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CHRNA7 GENE; CONTROLLED STUDY; FEMALE; GENE; GENE EXPRESSION; GENETIC ASSOCIATION; HETEROZYGOSITY; HIPPOCAMPUS; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REDUCTION; SCHIZOPHRENIA; SEX DIFFERENCE; WESTERN BLOTTING; ANIMAL; C3H MOUSE; GENETICS; GENOTYPE; KNOCKOUT MOUSE; METABOLISM; PATHOPHYSIOLOGY; SEXUAL DEVELOPMENT;

ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR; ANIMALS; BLOTTING, WESTERN; FEMALE; GENOTYPE; GLUTAMATE DECARBOXYLASE; HIPPOCAMPUS; MALE; MICE, INBRED C3H; MICE, KNOCKOUT; PARVALBUMINS; RECEPTORS, GABA-A; SEX CHARACTERISTICS;

EID: 84901416917     PISSN: 03064522     EISSN: 18737544     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2014.05.004     Document Type: Article

References (83)

1. Adams C.E., Yonchek J.C., Zheng L., Collins A.C., Stevens K.E. Altered hippocampal circuit function in C3H alpha7 null mutant heterozygous mice. Brain Res 2008, 1194:138-145.
2. Adams C.E., Yonchek J.C., Schulz K.M., Graw S.L., Stitzel J., Teschke P.U., Stevens K.E. Reduced Chrna7 expression in mice is associated with decreases in hippocampal markers of inhibitory function: implications for neuropsychiatric diseases. Neuroscience 2012, 207:274-282.
3. Arevalo-Serrano J., Sanz-Anquela J.M., Gonzalo-Ruiz A. Beta-amyloid peptide-induced modifications in alpha7 nicotinic acetylcholine receptor immunoreactivity in the hippocampus of the rat: relationship with GABAergic and calcium-binding proteins perikarya. Brain Res Bull 2008, 75:533-544.
4. Barch D.M., Ceaser A. Cognition in schizophrenia: core psychological and neural mechanisms. Trends Cogn Sci 2012, 16:27-34.
5. Baumgartner B.J., Harvey R.J., Darlison M.G., Barnes E.M. Developmental up-regulation and agonist-dependent down-regulation of GABAA receptor subunit mRNAs in chick cortical neurons. Brain Res Mol Brain Res 1994, 26:9-17.
6. Benes F.M., Lim B., Matzilevich D., Walsh J.P., Subburaju S., Minns M. Regulation of the GABA cell phenotype in hippocampus of schizophrenics and bipolars. Proc Natl Acad Sci U S A 2007, 104:10164-10169.
7. Beneyto M., Abbott A., Hashimoto T., Lewis D.A. Lamina-specific alterations in cortical GABA(A) receptor subunit expression in schizophrenia. Cereb Cortex 2011, 21:999-1011.
8. Ben-Shachar S., Lanpher B., German J.R., Qasaymeh M., Potocki L., Nagamani S.C., Franco L.M., Malphrus A., Bottenfield G.W., Spence J.E., Amato S., Rousseau J.A., Moghaddam B., Skinner C., Skinner S.A., Bernes S., Armstrong N., Shinawi M., Stankiewicz P., Patel A., Cheung S.W., Lupski J.R., Beaudet A.L., Sahoo T. Microdeletion 15q13.3: a locus with incomplete penetrance for autism, mental retardation, and psychiatric disorders. J Med Genet 2009, 46:382-388.
9. Berry A., Amrein I., Notzli S., Lazic S.E., Bellisario V., Giorgio M., Pelicci P.G., Alleva E., Lipp H.P., Cirulli F. Sustained hippocampal neurogenesis in females is amplified in P66(Shc-/-) mice: an animal model of healthy aging. Hippocampus 2012, 22:2249-2259.
10. Boucher J., Mayes A., Bigham S. Memory in autistic spectrum disorder. Psychol Bull 2012, 138:458-496.
11. Braakman H.M., van der Kruijs S.J., Vaessen M.J., Jansen J.F., Debeij-van Hall M.H., Vles J.S., Aldenkamp A.P., Backes W.H., Hofman P.A. Microstructural and functional MRI studies of cognitive impairment in epilepsy. Epilepsia 2012, 53:1690-1699.
12. Breese C.R., Adams C., Logel J., Drebing C., Rollins Y., Barnhart M., Sullivan B., Demasters B.K., Freedman R., Leonard S. Comparison of the regional expression of nicotinic acetylcholine receptor alpha7 mRNA and [125I]-alpha-bungarotoxin binding in human postmortem brain. J Comp Neurol 1997, 387:385-398.
13. Briggs S.W., Galanopoulou A.S. Altered GABA signaling in early life epilepsies. Neural Plast 2011, 2011:527605.
14. Brunig I., Penschuck S., Berninger B., Benson J., Fritschy J.M. BDNF reduces miniature inhibitory postsynaptic currents by rapid downregulation of GABA(A) receptor surface expression. Eur J Neurosci 2001, 13:1320-1328.
15. Coghlan S., Horder J., Inkster B., Mendez M.A., Murphy D.G., Nutt D.J. GABA system dysfunction in autism and related disorders: from synapse to symptoms. Neurosci Biobehav Rev 2012, 36:2044-2055.
16. Collin T., Chat M., Lucas M.G., Moreno H., Racay P., Schwaller B., Marty A., Llano I. Developmental changes in parvalbumin regulate presynaptic Ca2+ signaling. J Neurosci 2005, 25:96-107.
17. Dibbens L.M., Mullen S., Helbig I., Mefford H.C., Bayly M.A., Bellows S., Leu C., Trucks H., Obermeier T., Wittig M., Franke A., Caglayan H., Yapici Z., Sander T., Eichler E.E., Scheffer I.E., Mulley J.C., Berkovic S.F. Familial and sporadic 15q13.3 microdeletions in idiopathic generalized epilepsy: precedent for disorders with complex inheritance. Hum Mol Genet 2009, 18:3626-3631.
18. Duncan C.E., Webster M.J., Rothmond D.A., Bahn S., Elashoff M., Shannon Weickert C. Prefrontal GABA(A) receptor alpha-subunit expression in normal postnatal human development and schizophrenia. J Psychiatr Res 2010, 44:673-681.
19. Esclapez M., Houser C.R. Up-regulation of GAD65 and GAD67 in remaining hippocampal GABA neurons in a model of temporal lobe epilepsy. J Comp Neurol 1999, 412:488-505.
20. Fiedler B.J., Debus O.M., Neubauer B.A., Kienle M., Kurlemann G. P50 sensory gating deficit in children with centrotemporal spikes and sharp waves in the EEG. Neurosci Lett 2006, 393:206-210.
21. Freedman R., Wetmore C., Stromberg I., Leonard S., Olson L. Alpha-bungarotoxin binding to hippocampal interneurons: immunocytochemical characterization and effects on growth factor expression. J Neurosci 1993, 13:1965-1975.
22. Freund T.F. Interneuron diversity series: rhythm and mood in perisomatic inhibition. Trends Neurosci 2003, 26:489-495.
23. Gault L.M., Siegel R.E. Expression of the GABAA receptor delta subunit is selectively modulated by depolarization in cultured rat cerebellar granule neurons. J Neurosci 1997, 17:2391-2399.
24. Gonzalez-Burgos G., Lewis D.A. NMDA receptor hypofunction, parvalbumin-positive neurons, and cortical gamma oscillations in schizophrenia. Schizophr Bull 2012, 38:950-957.
25. Graef S., Schonknecht P., Sabri O., Hegerl U. Cholinergic receptor subtypes and their role in cognition, emotion, and vigilance control: an overview of preclinical and clinical findings. Psychopharmacology (Berl) 2011, 215:205-229.
26. Gutierrez M.L., Ferreri M.C., Gravielle M.C. GABA-induced uncoupling of GABA/benzodiazepine site interactions is mediated by increased GABA receptor internalization and associated with a change in subunit composition. Neuroscience 2013, 257C:119-129.
27. Hashimoto T., Bergen S.E., Nguyen Q.L., Xu B., Monteggia L.M., Pierri J.N., Sun Z., Sampson A.R., Lewis D.A. Relationship of brain-derived neurotrophic factor and its receptor TrkB to altered inhibitory prefrontal circuitry in schizophrenia. J Neurosci 2005, 25:372-383.
28. Hauser T.A., Kucinski A., Jordan K.G., Gatto G.J., Wersinger S.R., Hesse R.A., Stachowiak E.K., Stachowiak M.K., Papke R.L., Lippiello P.M., Bencherif M. TC-5619: an alpha7 neuronal nicotinic receptor-selective agonist that demonstrates efficacy in animal models of the positive and negative symptoms and cognitive dysfunction of schizophrenia. Biochem Pharmacol 2009, 78:803-812.
29. Heckers S., Konradi C. Hippocampal pathology in schizophrenia. Curr Top Behav Neurosci 2010, 4:529-553.
30. Helbig I., Mefford H.C., Sharp A.J., Guipponi M., Fichera M., Franke A., Muhle H., de Kovel C., Baker C., von Spiczak S., Kron K.L., Steinich I., Kleefuss-Lie A.A., Leu C., Gaus V., Schmitz B., Klein K.M., Reif P.S., Rosenow F., Weber Y., Lerche H., Zimprich F., Urak L., Fuchs K., Feucht M., Genton P., Thomas P., Visscher F., de Haan G.J., Moller R.S., Hjalgrim H., Luciano D., Wittig M., Nothnagel M., Elger C.E., Nurnberg P., Romano C., Malafosse A., Koeleman B.P., Lindhout D., Stephani U., Schreiber S., Eichler E.E., Sander T. 15q13.3 microdeletions increase risk of idiopathic generalized epilepsy. Nat Genet 2009, 41:160-162.
31. Holopainen I.E., Lauren H.B. Neuronal activity regulates GABAA receptor subunit expression in organotypic hippocampal slice cultures. Neuroscience 2003, 118:967-974.
32. Hoppman-Chaney N., Wain K., Seger P., Superneau D., Hodge J. Identification of single gene deletions at 15q13.3: further evidence that CHRNA7 causes the 15q13.3 microdeletion syndrome phenotype. Clin Genet 2013, 83:345-351.
33. Hosak L. New findings in the genetics of schizophrenia. World J Psychiatry 2013, 3:57-61.
34. Joshi S., Kapur J. N-methyl-D-aspartic acid receptor activation downregulates expression of delta subunit-containing GABAA receptors in cultured hippocampal neurons. Mol Pharmacol 2013, 84:1-11.
35. Kalkstein S., Hurford I., Gur R.C. Neurocognition in schizophrenia. Curr Top Behav Neurosci 2010, 4:373-390.
36. Kinney J.W., Davis C.N., Tabarean I., Conti B., Bartfai T., Behrens M.M. A specific role for NR2A-containing NMDA receptors in the maintenance of parvalbumin and GAD67 immunoreactivity in cultured interneurons. J Neurosci 2006, 26:1604-1615.
37. Koike K., Hashimoto K., Takai N., Shimizu E., Komatsu N., Watanabe H., Nakazato M., Okamura N., Stevens K.E., Freedman R., Iyo M. Tropisetron improves deficits in auditory P50 suppression in schizophrenia. Schizophr Res 2005, 76:67-72.
38. Konradi C., Yang C.K., Zimmerman E.I., Lohmann K.M., Gresch P., Pantazopoulos H., Berretta S., Heckers S. Hippocampal interneurons are abnormal in schizophrenia. Schizophr Res 2011, 131:165-173.
39. Kroes M.C., Fernandez G. Dynamic neural systems enable adaptive, flexible memories. Neurosci Biobehav Rev 2012, 36:1646-1666.
40. Lau C.G., Murthy V.N. Activity-dependent regulation of inhibition via GAD67. J Neurosci 2012, 32:8521-8531.
41. Leiser S.C., Bowlby M.R., Comery T.A., Dunlop J. A cog in cognition: how the alpha 7 nicotinic acetylcholine receptor is geared towards improving cognitive deficits. Pharmacol Ther 2009, 122:302-311.
42. Leonard S., Freedman R. Genetics of chromosome 15q13-q14 in schizophrenia. Biol Psychiatry 2006, 60:115-122.
43. Lisman J., Buzsaki G. A neural coding scheme formed by the combined function of gamma and theta oscillations. Schizophr Bull 2008, 34:974-980.
44. Lisman J.E., Coyle J.T., Green R.W., Javitt D.C., Benes F.M., Heckers S., Grace A.A. Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia. Trends Neurosci 2008, 31:234-242.
45. Luscher B., Fuchs T., Kilpatrick C.L. GABAA receptor trafficking-mediated plasticity of inhibitory synapses. Neuron 2011, 70:385-409.
46. Martin D.L., Tobin A.J. Mechanisms controlling GABA synthesis and degradation in the brain. GABA in the nervous system: the view at fifty years 2000, 25-41. Lippincott Williams and Wilkins, Philadelphia. D.L. Martin, R.W. Olsen (Eds.).
47. Miller D.T., Shen Y., Weiss L.A., Korn J., Anselm I., Bridgemohan C., Cox G.F., Dickinson H., Gentile J., Harris D.J., Hegde V., Hundley R., Khwaja O., Kothare S., Luedke C., Nasir R., Poduri A., Prasad K., Raffalli P., Reinhard A., Smith S.E., Sobeih M.M., Soul J.S., Stoler J., Takeoka M., Tan W.H., Thakuria J., Wolff R., Yusupov R., Gusella J.F., Daly M.J., Wu B.L. Microdeletion/duplication at 15q13.2q13.3 among individuals with features of autism and other neuropsychiatric disorders. J Med Genet 2009, 46:242-248.
48. Minzenberg M.J., Carter C.S. Developing treatments for impaired cognition in schizophrenia. Trends Cogn Sci 2012, 16:35-42.
49. Miranda J.D., Barnes E.M. Repression of gamma-aminobutyric acid type A receptor alpha1 polypeptide biosynthesis requires chronic agonist exposure. J Biol Chem 1997, 272:16288-16294.
50. Mizuno K., Giese K.P. Towards a molecular understanding of sex differences in memory formation. Trends Neurosci 2010, 33:285-291.
51. Mizuno K., Carnahan J., Nawa H. Brain-derived neurotrophic factor promotes differentiation of striatal GABAergic neurons. Dev Biol 1994, 165:243-256.
52. Moore M.D., Cushman J., Chandra D., Homanics G.E., Olsen R.W., Fanselow M.S. Trace and contextual fear conditioning is enhanced in mice lacking the alpha4 subunit of the GABA(A) receptor. Neurobiol Learn Mem 2010, 93:383-387.
53. Morellini F., Sivukhina E., Stoenica L., Oulianova E., Bukalo O., Jakovcevski I., Dityatev A., Irintchev A., Schachner M. Improved reversal learning and working memory and enhanced reactivity to novelty in mice with enhanced GABAergic innervation in the dentate gyrus. Cereb Cortex 2010, 20:2712-2727.
54. Mowry B.J., Gratten J. The emerging spectrum of allelic variation in schizophrenia: current evidence and strategies for the identification and functional characterization of common and rare variants. Mol Psychiatry 2013, 18:38-52.
55. Olincy A., Freedman R. Nicotinic mechanisms in the treatment of psychotic disorders: a focus on the alpha7 nicotinic receptor. Handb Exp Pharmacol 2012, 211-232.
56. Pagnamenta A.T., Wing K., Sadighi Akha E., Knight S.J., Bolte S., Schmotzer G., Duketis E., Poustka F., Klauck S.M., Poustka A., Ragoussis J., Bailey A.J., Monaco A.P. A 15q13.3 microdeletion segregating with autism. Eur J Hum Genet 2009, 17:687-692.
57. Pickard B. Progress in defining the biological causes of schizophrenia. Expert Rev Mol Med 2011, 13:e25.
58. Pimentel-Coelho P.M., Michaud J.P., Rivest S. Evidence for a gender-specific protective role of innate immune receptors in a model of perinatal brain injury. J Neurosci 2013, 33:11556-11572.
59. Piskulic D., Olver J.S., Norman T.R., Maruff P. Behavioural studies of spatial working memory dysfunction in schizophrenia: a quantitative literature review. Psychiatry Res 2007, 150:111-121.
60. Procaccini C., Maksimovic M., Aitta-Aho T., Korpi E.R., Linden A.M. Reversal of novelty-induced hyperlocomotion and hippocampal c-Fos expression in GluA1 knockout male mice by the mGluR2/3 agonist LY354740. Neuroscience 2013, 250:189-200.
61. Radek R.J., Robb H.M., Stevens K.E., Gopalakrishnan M., Bitner R.S. Effects of the novel alpha7 nicotinic acetylcholine receptor agonist ABT-107 on sensory gating in DBA/2 mice: pharmacodynamic characterization. J Pharmacol Exp Ther 2012, 343:736-745.
62. Ramirez M., Gutierrez R. Activity-dependent expression of GAD67 in the granule cells of the rat hippocampus. Brain Res 2001, 917:139-146.
63. Sakata A., Mogi M., Iwanami J., Tsukuda K., Min L.J., Fujita T., Iwai M., Ito M., Horiuchi M. Sex-different effect of angiotensin II type 2 receptor on ischemic brain injury and cognitive function. Brain Res 2009, 1300:14-23.
64. Saliba R.S., Michels G., Jacob T.C., Pangalos M.N., Moss S.J. Activity-dependent ubiquitination of GABA(A) receptors regulates their accumulation at synaptic sites. J Neurosci 2007, 27:13341-13351.
65. Sharp A.J., Mefford H.C., Li K., Baker C., Skinner C., Stevenson R.E., Schroer R.J., Novara F., De Gregori M., Ciccone R., Broomer A., Casuga I., Wang Y., Xiao C., Barbacioru C., Gimelli G., Bernardina B.D., Torniero C., Giorda R., Regan R., Murday V., Mansour S., Fichera M., Castiglia L., Failla P., Ventura M., Jiang Z., Cooper G.M., Knight S.J., Romano C., Zuffardi O., Chen C., Schwartz C.E., Eichler E.E. A recurrent 15q13.3 microdeletion syndrome associated with mental retardation and seizures. Nat Genet 2008, 40:322-328.
66. Stefansson H., Rujescu D., Cichon S., Pietilainen O.P., Ingason A., Steinberg S., Fossdal R., Sigurdsson E., Sigmundsson T., Buizer-Voskamp J.E., Hansen T., Jakobsen K.D., Muglia P., Francks C., Matthews P.M., Gylfason A., Halldorsson B.V., Gudbjartsson D., Thorgeirsson T.E., Sigurdsson A., Jonasdottir A., Bjornsson A., Mattiasdottir S., Blondal T., Haraldsson M., Magnusdottir B.B., Giegling I., Moller H.J., Hartmann A., Shianna K.V., Ge D., Need A.C., Crombie C., Fraser G., Walker N., Lonnqvist J., Suvisaari J., Tuulio-Henriksson A., Paunio T., Toulopoulou T., Bramon E., Di Forti M., Murray R., Ruggeri M., Vassos E., Tosato S., Walshe M., Li T., Vasilescu C., Muhleisen T.W., Wang A.G., Ullum H., Djurovic S., Melle I., Olesen J., Kiemeney L.A., Franke B., Sabatti C., Freimer N.B., Gulcher J.R., Thorsteinsdottir U., Kong A., Andreassen O.A., Ophoff R.A., Georgi A., Rietschel M., Werge T., Petursson H., Goldstein D.B., Nothen M.M., Peltonen L., Collier D.A., St Clair D., Stefansson K. Large recurrent microdeletions associated with schizophrenia. Nature 2008, 455:232-236.
67. Stephens S.H., Logel J., Barton A., Franks A., Schultz J., Short M., Dickenson J., James B., Fingerlin T.E., Wagner B., Hodgkinson C., Graw S., Ross R.G., Freedman R., Leonard S. Association of the 5'-upstream regulatory region of the alpha7 nicotinic acetylcholine receptor subunit gene (CHRNA7) with schizophrenia. Schizophr Res 2009, 109:102-112.
68. Stephens S.H., Franks A., Berger R., Palionyte M., Fingerlin T.E., Wagner B., Logel J., Olincy A., Ross R.G., Freedman R., Leonard S. Multiple genes in the 15q13-q14 chromosomal region are associated with schizophrenia. Psychiatr Genet 2012, 22:1-14.
69. Thompson Ray M., Weickert C.S., Wyatt E., Webster M.J. Decreased BDNF, trkB-TK+ and GAD67 mRNA expression in the hippocampus of individuals with schizophrenia and mood disorders. J Psychiatry Neurosci 2011, 36:195-203.
70. Thomsen M.S., Hansen H.H., Timmerman D.B., Mikkelsen J.D. Cognitive improvement by activation of alpha7 nicotinic acetylcholine receptors: from animal models to human pathophysiology. Curr Pharm Des 2010, 16:323-343.
71. Todtenkopf M.S., Benes F.M. Distribution of glutamate decarboxylase65 immunoreactive puncta on pyramidal and nonpyramidal neurons in hippocampus of schizophrenic brain. Synapse 1998, 29:323-332.
72. Tregellas J.R., Tanabe J.L., Miller D.E., Ross R.G., Olincy A., Freedman R. Neurobiology of smooth pursuit eye movement deficits in schizophrenia: an fMRI study. Am J Psychiatry 2004, 161:315-321.
73. Tregellas J.R., Davalos D.B., Rojas D.C., Waldo M.C., Gibson L., Wylie K., Du Y.P., Freedman R. Increased hemodynamic response in the hippocampus, thalamus and prefrontal cortex during abnormal sensory gating in schizophrenia. Schizophr Res 2007, 92:262-272.
74. van Elst L.T., Valerius G., Buchert M., Thiel T., Rusch N., Bubl E., Hennig J., Ebert D., Olbrich H.M. Increased prefrontal and hippocampal glutamate concentration in schizophrenia: evidence from a magnetic resonance spectroscopy study. Biol Psychiatry 2005, 58:724-730.
75. Van Kampen M., Selbach K., Schneider R., Schiegel E., Boess F., Schreiber R. AR-R 17779 improves social recognition in rats by activation of nicotinic alpha7 receptors. Psychopharmacology (Berl) 2004, 172:375-383.
76. Wallace T.L., Bertrand D. Alpha7 neuronal nicotinic receptors as a drug target in schizophrenia. Expert Opin Ther Targets 2013, 17:139-155.
77. Wallace T.L., Porter R.H. Targeting the nicotinic alpha7 acetylcholine receptor to enhance cognition in disease. Biochem Pharmacol 2011, 82:891-903.
78. Wei J., Davis K.M., Wu H., Wu J.Y. Protein phosphorylation of human brain glutamic acid decarboxylase (GAD)65 and GAD67 and its physiological implications. Biochemistry 2004, 43:6182-6189.
79. Williams T.J., Nuechterlein K.H., Subotnik K.L., Yee C.M. Distinct neural generators of sensory gating in schizophrenia. Psychophysiology 2011, 48:470-478.
80. Wu Y.C., Hill R.A., Klug M., van den Buuse M. Sex-specific and region-specific changes in BDNF-TrkB signalling in the hippocampus of 5-HT1A receptor and BDNF single and double mutant mice. Brain Res 2012, 1452:10-17.
81. Wyllie D.J., Livesey M.R., Hardingham G.E. Influence of GluN2 subunit identity on NMDA receptor function. Neuropharmacology 2013, 74:4-17.
82. Yamada M.K., Nakanishi K., Ohba S., Nakamura T., Ikegaya Y., Nishiyama N., Matsuki N. Brain-derived neurotrophic factor promotes the maturation of GABAergic mechanisms in cultured hippocampal neurons. J Neurosci 2002, 22:7580-7585.
83. Zhang Z.J., Reynolds G.P. A selective decrease in the relative density of parvalbumin-immunoreactive neurons in the hippocampus in schizophrenia. Schizophr Res 2002, 55:1-10.